Form 4: Quantum-Si CEO Granted Significant Equity Awards

Quantum-Si Inc.'s President and CEO, Jeffrey Alan Hawkins, received substantial grants of restricted stock units and stock options, aligning his incentives with long-term company performance.

Summary

• Jeffrey Alan Hawkins, President & CEO and Director of Quantum-Si Inc. (QSI), acquired 1,305,606 Restricted Stock Units (RSUs) on March 12, 2026.
• Each RSU represents the right to receive one share of Class A Common Stock upon vesting, with vesting occurring in four equal annual installments beginning April 20, 2027, subject to continued service.
• Hawkins also acquired 1,561,695 stock options (right to buy) on March 12, 2026, with an exercise price of $0.976 per share.
• These stock options will vest in equal quarterly installments beginning June 20, 2026, subject to continued service, and have an expiration date of March 12, 2036.
• Following these transactions, Hawkins beneficially owns 3,883,624 shares of Class A Common Stock and 1,561,695 derivative securities (stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as substantial equity grants to the CEO with long vesting periods strongly align management's interests with long-term shareholder value creation, signaling confidence and commitment.

Positives

• The significant equity grants to the President & CEO align his long-term financial interests directly with those of the shareholders, promoting sustained company performance.
• The multi-year vesting schedules for both RSUs and stock options incentivize the CEO to remain with the company and drive value over an extended period.

Future Outlook

The equity grants, with their multi-year vesting schedules, indicate a long-term commitment from the CEO to Quantum-Si Inc.'s future performance and growth, aligning executive incentives with shareholder value creation over the coming years.

Industry Context

StockSavvy.ai notes that significant equity-based compensation, particularly with long vesting periods, is a common practice in the biotechnology and life sciences sectors for retaining key executives and motivating them to achieve long-term strategic objectives. This grant is consistent with industry trends to align leadership incentives with shareholder returns.

Comparison to Industry Standards

• Equity grants with multi-year vesting schedules are standard practice across the technology and life sciences industries, comparable to compensation structures at companies like Illumina or Pacific Biosciences, which often use similar mechanisms to retain and incentivize top talent.
• The combination of RSUs and stock options provides a balanced incentive, offering both retention value (RSUs) and upside potential (options), a common strategy seen in competitive executive compensation packages.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of CEO's interests with long-term company performance and shareholder value.
• Employees: May signal stability and confidence in leadership, potentially boosting morale.
• Management: Provides significant long-term incentives and compensation, subject to continued service and performance.

Next Steps

• Vesting of 1,561,695 stock options in equal quarterly installments beginning June 20, 2026.
• Vesting of 1,305,606 Restricted Stock Units in four equal annual installments beginning April 20, 2027.

Key Dates

Keywords

QSI, Quantum-Si, Jeffrey Alan Hawkins, RSU, Stock Option, Insider Transaction, Equity Grant, CEO Compensation, Form 4